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Enterovirus 71 (EV71) is a highly infectious major causative agent of hand, foot, and mouth disease (HFMD) which could lead to severe
neurological complications. There is currently no effective therapy against EV71. In this study, RNA interference (RNAi) is employed as a
therapeutic approach for specific viral inhibition. Various regions of the EV71 genome were targeted for inhibition by chemically synthesized
siRNAs. Transfection of rhabdomyosarcoma (RD) cells with siRNA targeting the 3VUTR, 2C, 3C, or 3D region significantly alleviated
cytopathic effects of EV71. The inhibitory effect was dosage-dependent with a corresponding decrease in viral RNA, viral proteins, and
plaque formations by EV71. Viral inhibition of siRNA transfected RD cells was still evident after 48 h. In addition, no significant adverse off-
target silencing effects were observed. These results demonstrated the potential and feasibility for the use of siRNA as an antiviral therapy for
EV71 infections.
D 2005 Elsevier Inc. All rights reserved.Keywords: Enterovirus 71; RNA interference; 3VUTR; siRNA; Viral inhibitionIntroduction
Enterovirus 71 (EV71) belongs to the family Picorna-
viridae under the genus Enterovirus and is a Human
enterovirus A species (Miller, 1997). It is a positive single-
stranded RNA virus with a non-enveloped capsid and a
genome size of 7411 nucleotides. It has caused significant
mortality worldwide in recent years (Ho et al., 1999).
EV71 is one of the main etiological agents of hand, foot,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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plexes; RNAi, ribonucleic acid interference; siRNA, small interfering
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exanthem which mainly affects young children (<6 years
of age), resulting in the appearance of vesicular rashes on
hands, feet, and buccal mucosa. EV71-infected children
could develop severe neurological complications that lead
to rapid clinical deterioration and death (Chang et al.,
1999; Lum et al., 1998; McMinn et al., 2001). With the
emergence of EV71 in Asia as a major causative agent of
HFMD fatalities in recent years and the ineffectiveness of
anti-enteroviral therapy, there is a need to find a specific
antiviral therapy. RNA interference (RNAi) holds promise
as the inhibition of replication of poliovirus (Gitlin et al.,
2002) and rhinovirus (Phipps et al., 2004) was observed in
infected tissue culture cells.
RNAi is a native and specific post-transcriptional gene
silencing mechanism. The process is initiated by double-
stranded RNA (dsRNA) molecules (Fire et al., 1998). The
dsRNA is processed by the RNase III-like enzyme Dicer
into small interfering RNAs (siRNA) of 21–23 base pairs.
The siRNA molecule then induces the formation of the005) 72 – 79
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nize and degrade homologous target mRNAs. Long dsRNA
will induce the interferon response in mammalian cells
which lead to the inhibition of protein synthesis by the
activation of the PKR pathway and the activation of RNase
L (Sledz et al., 2004). To circumvent the use of dsRNA in
RNAi, Elbashir et al. (2001a, 2001b) had successfully used
siRNA for silencing genes in mammalian system (Elbashir
et al., 2001a, 2001b).
In this study, we tested chemically synthesized siRNAs
for the specific inhibition of replication of EV71. Viral
RNA, viral protein, plaque forming units, and cytopathic
effects of infected rhabdomyosarcoma cells were examined
as the indicators of targeted gene silencing by siRNA. We
demonstrated that chemically synthesized siRNAs targeting
at the 3VUTR, 2C, 3Cpro, or 3Dpol of the EV71 genome are
capable of inhibiting viral replication in a specific and dose-
dependent manner.Results
Selection of EV71 specific siRNA and transfection efficiency
The design of the siRNAs was based on general
guidelines (Elbashir et al., 2001a, 2001b). Four synthetic
19-nucleotide siRNA duplexes targeting the non-translated
regions and non-structural genes within the EV71 genomic
domains: 3VUTR, 2C, 3Cpro, and 3Dpol were designed (Table
1). Non-specific scrambled sequences with the same
sequence composition as si-3VUTR served as a specificity
control.
Fluorescein-labeled si-3VUTR duplexes were used to
assay for the transfection efficiency of siRNA into the RD
cell lines under study. Different concentrations of labeled
siRNAwere used to check for the transfection efficiency. At
24 h post-transfection with 1 nM, 50 nM, and 100 nM
labeled si-3VUTR, the percentage of fluorescein-labeled RD
cells was 72 T 1%, 83 T 1%, and >95%, respectively. The
fluorescein-labeled siRNAwas localized in the cytoplasm of
the cell (data not shown).Table 1
Chemically synthesized siRNA molecules corresponding to the indicated segments
siRNA Nucleotide sequence
si-3VUTR 5V-UCU GGU CGU GUU AAU GAC U T
5V-AGU CAU UAA CAC GAC CAG A T
si-2C 5V-A ACC AGA UCA CGA ACU UGG T
5V-CCA AGU UCG UGA UCU GGU U T
si-3C 5V-GAG CUA CUU UGC GAG UAU GC
5V-UGC AUA CUC GCA AAG UAG CUC
si-3D 5V-GCU ACU UUG GGA UGC A TT-3V
5V-UGC AUA CUC GCA AAG UAG C T
Scrambled scr 5V-AGU UAC CGA UAA CCC AAG A T
5V-UCU UGG GUU A UCG GAU ACU TCell growth and viability assay
Cell growth and viability were used as parameters to
determine whether the transfection agent or siRNAs
introduced into the cells could result in any non-specific
cytotoxic effects. Using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt (MTS) reagent, cell viability assays were
performed at 1 and 2 days post-transfection. All the siRNAs
used in the experiment did not have any deleterious effects
on cell growth and viability (data not shown).
siRNAs delayed cytopathic effects and increased cell
viability in EV71-infected RD cells
RD cells were transfected with chemically synthesized
siRNAs to evaluate their inhibitory effects on viral
replication. In microscopic observations of RD cells
treated with si-3VUTR, the siRNA targeting at the 3VUTR
showed that cytopathic effects (CPE) in RD cells were
delayed by up to 48 h post infection (h.p.i). RD cells that
were treated with increasing concentrations of si-3VUTR
were found to have decreased CPE (Fig. 1). The dosage-
dependent viral inhibitory effect when using siRNAs such
as si-2C, si-3C, and si-3D was also evident in RD cell
lines, delaying CPE for up to 48 h.p.i. The 3VUTR
scrambled siRNA failed to protect against CPE in EV71-
infected RD cells, even when it was used at 100 nM. The
treatment of RD cells with the sense or antisense strand of
si-3VUTR at 100 nM also resulted in total CPE at 48 h.p.i.
The protective effect of the siRNAs over a period of time
after EV71 infection was also evaluated. At 24 h.p.i, the
viability of cells transfected with the various siRNAs was
comparable to the uninfected control cells. At 48 h.p.i,
approximately 72% of si-2C, 82% of si-3D, and 70% of
si-3VUTR transfected cells were viable at 48 h.p.i. In
contrast, the untreated and mock-transfected cells had
significantly lowered viability at 48 h.p.i. However,
despite the initial protective effect, prolonged incubation
up to 72 h.p.i led to total cell death, even after the














Fig. 1. RD cells infected with EV71 showing CPE. RD cells were transfected with chemically synthesized siRNA targeting at the 3VUTR and then infected with
60 pfu of EV71. CPE was first observed at 20 h.p.i., and the pictures were taken at 48 h.p.i. In panel A, cells were not pretreated with siRNA and were
subsequently infected with EV71. Panel B showed RD cells treated with Lipofectamine 2000 and were infected with EV71. Panel C showed uninfected healthy
RD cells. Panels D to F are EV71-infected cells after transfection with 1 nM si-3VUTR D, 50 nM si-3VUTR E, and 100 nM si-3VUTR F.
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Plaque assay was carried out to evaluate the effectiveness
of siRNA in reducing viable virus count. RD cells were
infected with 60 pfu of EV71. Plaque assays showed that RD
cells transfected with si-3VUTR, si-2C, si-3C, or si-3D had
reduced plaque formations (Fig. 2). Mock-transfected cells
did not exhibit any reduction in plaques. Cells transfected
with the siRNA targeting at the 3Dpol gene were found to
exert the most potent antiviral effect in concentrations being
tested followed by siRNA targeting the 3Cpro, 2C, and
3VUTR (Table 2). When 50 nM or 100 nM of single-stranded
antisense siRNAwas targeted at the 3VUTR, slight protectionagainst viral infections was observed. The sense strand of si-
3VUTR did not reduce plaque formations significantly at 50
nM and 100 nM. The non-specific scrambled duplex siRNA
of 3VUTR did not reduce plaque formation (Fig. 3).
siRNA treatment of RD cells reduced EV71 specific RNA
Using real-time reverse transcription PCR based on
hybridization probes targeting at the VP1 region of EV71,
we quantified the reduction in viral titer after subjecting the
RD cells to treatment with various siRNAs. Treatment of RD
cells with siRNAs targeting the 2C, 3C, 3Dpol, and 3VUTR
genes of EV71 resulted in a dose-dependent decrease in
Fig. 2. RD cells treated with the siRNA targeting at the 2C gene (si-2C)
demonstrated reduced plaque formations in a dosage-dependent manner.
Transfection with siRNA was carried out 24 h prior to infecting the cells
with 60 pfu of EV71. In panel A, cells were left untreated and then infected
(CV). In panel B, mock-transfected cells were infected with EV71 (CVT).
In panels D, E, and F, cells were treated with 1 nM, 50 nM, and 100 nM of
si-2C, respectively and then challenged with EV71. Panel C shows non-
infected cell monolayer. RD cell monolayer was stained with 1% crystal
violet. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
Fig. 3. Dose-dependent inhibitory effects of various siRNAs on plaque
formation in RD cells. Cells were left untreated and infected with 60 pfu of
EV71 (CV), or transfected with Lipofectamine 2000 and subsequently
infected (CVT), or transfected with 1–100 nM of si-2C, or si-3C, or si-3D,
or si-3VUTR, or the sense strand of 3VUTR (S), or the antisense strand of
3VUTR (AS), or the scrambled siRNA sequences (SC) at 24 h prior to EV71
infection. Plaque reductions were assayed at 48 h.p.i. The data shown
represent the mean T SD (n = 4). *P < 0.01. ANOVA analysis, for
comparison between CVT and other treatments.
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RD cells with 100 nM of si-2C, si-3C, si-3D, and si-3VUTR
resulted in viral titer reductions of 54.0 T 4.0%, 76.1 T 4.0%,
77.5 T 2.1%, and 44.1 T 5.9%, respectively (Table 2). The
transfection of RD cells with the antisense sequence of
3VUTR at 50 nM resulted in a slight reduction of approx-
imately 18.5 T 3.5%. However, the inhibition effect was not
enhanced when the antisense 3VUTR sequence was used at
100 nM (Table 2). In contrast, the sense and scrambled
sequences of 3VUTR did not decrease viral RNA.
siRNA-treated RD cells reduced EV71 specific proteins
In order to investigate whether the reduction in specific
viral RNA correlated with a down-regulation in specific viral
protein, Western blotting using monoclonal antibody against
EV71 VP1 structural protein was carried out. We chose si-3D
and si-2C to assay for the subsequent reduction in viral
proteins. It is evident from the results that the siRNA targetingTable 2
Comparative percentage reduction of viral load between data from real-time PCR
siRNA 1 nM 50 nM
Viral RNA




(mean T SD %
si-2C – 50.9 T 5.4 50.8 T 1.9
si-3C 18.0 T 3.0 58.7 T 2.0 56.0 T 2.0
si-3D 18.3 T 2.1 60.1 T 2.1 59.9 T 1.5
si-3VUTR – 36.9 T 3.4 12.0 T 2.1
ss-3VUTR – 6.7 T 5.8 –
as-3VUTR – 8.2 T 6.9 18.5 T 3.5
sc-3VUTR – – –
– : Denotes no reduction.at the 2C and 3Dpol genes of the EV71 genome significantly
reduced the amount of detectable VP1 in a dose-dependent
manner (Fig. 4). In contrast, the transfection of RD cells with
the siRNA carrying the non-specific scrambled sequences of
3VUTR failed to yield any reduction in the synthesis of VP1.
Similar trend was observed when si-3C was used (data not
shown). These results were consistent with the data obtained
at the RNA level by real-time PCR-based assays.
The specificity of the siRNA-mediated viral inhibition effect
To test for the specificity of RNAi, the effects of si-2C,
si-3D, and si-3VUTR on the expression of endogenous PKR






(mean T SD %)
Plaque reduction
(%)
68.5 T 4.8 54.0 T 4.0 87.8 T 4.1
71.1 T 2.0 76.1 T 4.0 88.7 T 3.8
73.8 T 2.9 77.5 T 2.1 89.3 T 4.0
47.6 T 4.6 44.1 T 5.9 59.2 T 6.9
17.9 T 6.0 18.5 T 9.7 10.0 T 1.0
27.2 T 2.9 18.5 T 3.5 25.7 T 2.5
– – –
Fig. 4. Western blot analysis of EV71 VP1. Approximately 1.0  106 RD
cells were transfected with si-2C or si-3D at various concentrations and
subsequently infected with the virus. The amount of EV71 structural
protein, VP1, was reduced upon treatment of RD cells with si-2C and si-3D.
VP1 decrease was determined through Western blotting using anti-EV71
monoclonal antibody (Chemicon) (upper panel). Internal loading control
h-actin was detected using anti-h-actin (Sigma) (lower panel).
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30 min, 60 min, and 90 min after siRNA entry. The cells
transfected with the various siRNAs showed similar levels
of PKR as the control cells (C) at various time-points post-
transfection (Fig. 5).Discussion
The development and use of antivirals, like enviroxime
(Heinz and Vance, 1995), pleconaril (Pevear et al., 1999),
and 3C protease inhibitors (Patick et al., 1997) for treating
enterovirus infections showed variable effectiveness against
the neurotropic EV71 (Robart et al., 1998). As a result, there
is a great interest in exploring new antiviral therapeutic
strategies against EV71 infection. RNAi has been success-
fully applied as a potent antiviral against the human
immunodeficiency virus (Capodici et al., 2002), hepatitis
B virus (Li et al., 2004), poliovirus (Gitlin et al., 2002), and
rhinovirus (Phipps et al., 2004).
The selective inhibition of EV71 has been demonstrated
using plasmid-based shRNA (Lu et al., 2004). The use of
recombinant vector producing siRNAs targeting EV71 was
shown to inhibit viral replication in both HeLa and Vero cells
(Lu et al., 2004). However, plasmid-derived shRNAs are
widely used as inexpensive proof-of-concept studies and are
unlikely to be a method employed for viral gene therapy. The
main obstacle in achieving in vivo gene silencing by RNAiFig. 5. Western blot analysis of dsRNA-activated protein kinase (PKR) (top panel)
at various time-points after transfection. Cells were transfected with 100 nM of si-
cells (CV) and EV71-infected mock-transfected RD cells (CVT) were used as p
negative control for interferon activation. At 30, 60, and 90 min post-transfection a
h-actin expression using specific antibodies. The h-actin Western blot demonstraagainst EV71 is its delivery across the blood–brain barrier
(BBB) into the CNS, which is highly immunogenic (Trulzsch
and Wood, 2004). Although the expression of plasmid-
derived shRNAs can be tightly regulated and also tissue-
specific expression cassettes can be incorporated, the intrinsic
size of plasmid-derived shRNAs and thus its problems in
delivery are drawbacks for its use as a possible antiviral
therapy. Furthermore, the difficulty to directly control the
transcriptional efficiency and dosage of the plasmid-derived
shRNAs intracellularly poses a problem for pharmacoki-
netics studies. Viral-vector derived shRNAs have been
successfully employed for gene knockdowns. The need for
specific delivery to the target cells can also be addressed by
the use of viral-based vectors, however, the use of viral
vectors is plagued with problems like immunogenicity and
random integration into host-genome, especially for adeno-
viral-based vector and lentivirus-based vector, respectively.
As viral infection is transient in nature, it is unnecessary
to have a long-lasting viral knockdown effect, which might
result in non-specific adverse effects. Chemically synthe-
sized siRNA used to mediate RNAi against viruses could be
the most relevant strategy for genetic antiviral therapy as it
is straightforward and non-immunogenic (Trulzsch and
Wood, 2004). In addition, chemically synthesized siRNA
is amenable to various chemical modifications or conjuga-
tions to increase its stability and specificity for cellular
uptake. Chemically stabilized and cholesterol-conjugated
siRNAs have been shown to silence endogenous genes by
means of a systemic delivery of the modified siRNA into
mouse models (Soutschek et al., 2004). This is especially
relevant to EV71 infection in which the systemic delivery of
the modified synthetic siRNAs could be engineered to be
highly tissue-specific.
In this study, by targeting the non-structural genes of
EV71, namely 2C, 3Cpro, 3Dpol, and 3VUTR, four separate
lines of evidence have established that RNAi can be used to
suppress EV71 replication. These are: (1) chemically
synthesized siRNA significantly reduced viral RNA in
infected cells; (2) EV71 specific protein (VP1) was visibly
reduced in cells treated with the siRNAs; (3) viable viral
count and infectivity measured by plaque assay were
significantly reduced upon siRNA treatment; (4) the cellsshowing no significant changes in the expression level of endogenous PKR
2C, si-3D, or si-3VUTR of the EV71 genome. Untreated EV71-infected RD
ositive controls for interferon activation. Untreated cells (C) were used as
nd infection, the total cell lysates were collected and analyzed for PKR and
tes equal loading of total protein (lower panel).
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formation of cytopathic effects (CPE) for up to 48 h.
The use of siRNA as an antiviral agent could lead to a
selective pressure on the siRNA target, which might result
in the appearance of escape variants due to the changes in
the target sequence as has been observed with poliovirus
(Gitlin et al., 2002). To minimize this possibility, EV71
target sequences that were chosen for the design of the
siRNA were those that were highly conserved and are
therefore less likely to alter and generate escape mutants. All
four chemically synthesized siRNAs, namely, si-3VUTR,
si-2C, si-3C, and si-3D, were capable of eliciting a dosage-
dependent inhibition of EV71 replication. The dosage-
dependent viral inhibitory effect of the siRNAs correlated
with their transfection efficiencies into the cells.
The plaque assay data correlated well with that from the
real-time PCR assay, the most effective inhibition of viral
replication was observed with si-3D followed by si-3C, si-
2C, and si-3VUTR. The 3Dpol gene encodes the viral RNA-
dependent RNA polymerase, which oligomerizes into a form
most suited to the elongation and RNA-binding activity of
the polymerase. As the 3Dpol gene product acts in concert
with other viral and cellular factors to be the indispensable
component facilitating viral replication, it is therefore
expected that its down-regulation would produce the most
effective inhibitory effect on viral replication. The 3C region
encodes for a protease, which performs majority of the
secondary processing steps in the polyprotein. Studies from
polioviruses have indicated two cleavages being carried out
with 3CD, which is the precursor of 3C. Whether EV71
exhibits the same specific 3CD proteolytic activity is still
unknown, however, our inhibition data suggest that siRNA
targeting either at the 3Cpro or the 3Dpol region in the viral
genome elicited comparable and most effective viral
inhibition. In EV71, specific functions of the 2C protein
and the 3VUTR have yet to be identified. The 2C protein has
been implicated to be involved in the initiation of negative
and positive-strand synthesis and is known to associate with
the 3VUTR of negative-strand viral RNA replication inter-
mediates (Banerjee et al., 1997). Our results also correlate
with the finding by Lu et al. (2004) who used plasmid-
derived shRNA for viral inhibition studies. Both studies
showed that targeting at the viral RNA-dependent RNA
polymerase, 3Dpol, is the most effective in inhibiting viral
replication. We have further established that targeting at the
other EV71 non-structural regions like 3Cpro, 2C, and 3VUTR
is also effective in inhibiting viral replication.
It is important to assess whether single-stranded sense
siRNA or antisense siRNA could elicit similar inhibitory
effect. Using single-stranded 5V-phosphorylated sense or
antisense siRNA, only slight inhibitory effect (<20%) was
observed at high concentrations (100 nM) of the antisense
strand and is not as effective when compared with the use of
duplex siRNA at the same concentration. This is due to the
inefficient reconstitution of RISC when single-stranded
siRNA was used (Martinez et al., 2002).The protection of RD cells against CPE by various
siRNAs over a time-course of EV71 infection was assessed.
The CPE was delayed by up to 48 h for the cells transfected
with the four siRNAs. However, despite the initial
protection, prolonged incubation for up to 72 h.p.i resulted
in cell death. The loss of protection conferred by the
siRNA is likely to be due to the decrease in the siRNA
concentration as the cell population divides.
In principle, it is possible that the inhibition of viral
replication is caused by an interferon-mediated response,
which can be activated by short dsRNA (Sledz et al., 2004).
It is therefore important to find out whether the siRNAs
used in the study are capable of eliciting off-target effects,
like the activation of the interferon (IFN) response. A
Western blot conducted with a monoclonal antibody against
protein kinase R (PKR) showed that the IFN pathway is not
engaged after siRNA transfection. Cell viability was used
as a global indicator to check for the adverse effects of IFN
activation, and it was not compromised during the 48 h
time period post-transfection with all the siRNAs used in
the experiment. The lack of the IFN response at the global
level lends optimism to the hope that siRNA of 21 nt
targeted to EV71 could be a promising antiviral for EV71
infections.
In conclusion, this study demonstrates that RNAi
mediated by chemically synthesized siRNA can be used
as a possible therapeutic strategy to inhibit EV71 replication
in human cells. RNAi using chemically synthesized
oligonucleotides si-2C, si-3C, si-3D, and si-3VUTR might
offer an important alternative for treatments against EV71.
Given the rapid strides being made in the field, especially
regarding in vivo delivery methods, the use of siRNA as an
antiviral therapeutic approach has great potential.Materials and methods
Cell culture
Rhabdomyosarcoma (RD) cells were routinely grown in
minimum essential medium (Gibco, Boston, MA, USA)
supplemented with 5% fetal calf serum, 1% sodium
pyruvate, and 1.5% sodium bicarbonate.
Design and synthesis of double stranded short interfering
RNA (siRNA)
21-nt double-stranded siRNA sequences were designed
with 3V-dTT extensions against 3VUTR, and 2C, 3Cpro, and
3Dpol of EV71. A scrambled sequence with the same base
composition as si-3VUTR and single-stranded sequence of
the sense and antisense of 3VUTR-31 were used as controls.
All the siRNAs and control sequences were listed in Table
1. Fluorescein-labeled si-3VUTR was also synthesized. The
label was on the 3V end of the sense strand. The siRNA
molecules were synthesized by Proligo, Singapore.
Table 3
Probes and primers used for detection of EV71
Name Nucleotide sequence Nucleotide location
VP1-Fwd 5V-GAG AGT TCT ATA GGG GAC AGT-3V 2466–2486
VP1-Rev 5V-AGC TGT GCT ATG TGA ATT AGG AA-3V 2669–2647
EVpprot_FL 5V-GTG TGT CTT GGC CGG TAG GTG CCG GT-3V 2538–2513
EVpprot_LC 5V-GAG CTC GGG TGA GGG CTC TGC TCA C-3V 2511–2487
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Rhabdomyosarcoma cells (5  104) were seeded into
each well of a 24-well plate and allowed to recover for
24 h, and the growth medium in each well was replaced
with 500 Al of pre-warmed reduced serum medium, OPTI-
MEM I (Gibco, Boston, MA,USA), for another 24 h.
Before transfection, the appropriate amount of siRNAs
(1, 50, or 100 nM) was diluted in 50 Al of OPTI-MEM I.
In another tube, 1 Al of Lipofectamine 2000 was also
diluted in 50 Al of OPTI-MEM I. After incubation at
room temperature for 5 min, these two solutions were
mixed gently and incubated for 20 min at room temper-
ature to allow the siRNA:lipofectamine 2000 complexes
to form. Then, 100 Al of the complexes was added to
each well and mixed gently by rocking the plate back and
forth. Mock transfections were carried out as described
above but with the omission of siRNA. After 24 h, each
of the wells was infected with EV71 at an MOI of 10. At
48 h post-infection, total RNA was extracted from each
well using TRIzol LS reagent (Invitrogen Life Technol-
ogies, Carlsbad, CA).
To estimate transfection efficiency, cells were grown on
Labtek Permanox Chamberslide (Nunc, Germany). At 24 h
post-transfection, cells were washed twice with phosphate-
buffered saline (PBS) and fixed with 4% paraformaldehyde
for 30 min. The cells were then washed again with PBS, and
a drop of Vectashield mounting medium (Vector Laborato-
ries, USA) containing propidium iodide was then added.
Cells were observed using Olympus BX60 fluorescent
microscope. The percentage of fluorescein-labeled cells in
five randomly selected fields from three independent
experiments was determined.
Cell viability assay
To assay for cell viability due to the toxicity of the
transfection agent, RD cells were seeded in a 24-well plate.
Transfection and treatment of cells were performed follow-
ing the methods already described above. At 1 and 2 days
post-transfection, cells were trypsinized, and a 100 Al
aliquot of the resuspended cells was transferred to 96-well
plate in triplicates. 20 Al of MTS/PMS reagent (Promega,
USA) was then added into each well. After incubation at
37 -C for 1 h, the absorbance at 490 nm was measured. All
assays were performed in triplicate and as two independent
experiments.Real-time reverse transcription (RT) PCR detection of EV71
using hybridization probes
Primers and hybridization probes for the real-time RT-
PCR were designed, and a BLAST search was conducted
against Genbank sequences. The probes and primers were
synthesized by Proligo, Singapore (Table 3). Following
reverse transcription, the cDNA was subjected to 40 PCR
cycles of amplification at 60 -C for 15 s and at 72 -C
for 17 s in the Roche LightCycler (Roche Molecular
Biochemicals, Germany). Absolute quantitation of viral
RNA was calculated using the standard curve previously
created.
SDS-PAGE and Western blot analysis
RD cells were grown in 6-well plate according to the
experimental set up described earlier. At 48 h post-
transfection, the cells were harvested for total proteins.
The cells were lysed using 125 Al of CelLytic M Cell Lysis
Reagent (Sigma, USA). An aliquot of 30 Al of each lysate
was electrophoresed in a denaturing 10% polyacrylamide
gel. Western blotting was performed following standard
procedures. The detection procedure based on chromogenic
method made use of monoclonal EV71 antibody (Chemicon
International, USA), anti-PKR (Sigma, USA), and h-actin
antibody (Sigma, USA).
Plaque assay of EV71-infected cells
To determine the viral infectivity of EV71 after
siRNA treatment, plaque assays were carried out after
the transfection protocol. One milliliter of 1% w/v
carboxymethylcellulose (CMC) in 2 growth medium
was layered onto the infected cell monolayer. The plates
were incubated at 37 -C in for 48 h. Plaques of EV71
viruses were observed by fixing with 20% formalin in
PBS and staining with 1% crystal violet for 30 min at
room temperature.Acknowledgments
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